Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer
Paul Cottu, Tomas Pascual, Jerôme Lemonnier, Huilin Hu, Estelle Roux, Roisin M Connolly, Cynthia X Ma, Antonio C Wolff, Thayane Crestani, Pablo Tolosa, Juan M Ferrero-Cafiero, Antonio Mulero-Sánchez, Fernando Salvador, Guillermo Villacampa, Joaquín Gavilá, Thibault de La Motte Rouge, Aleix Prat · 2026
Read Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer by Paul Cottu, Tomas Pascual, Jerôme Lemonnier, Huilin Hu, Estelle Roux, Roisin M Connolly, Cynthia X Ma, Antonio C Wolff, Thayane Crestani, Pablo Tolosa, Juan M Ferrero-Cafiero, Antonio Mulero-Sánchez, Fernando Salvador, Guillermo Villacampa, Joaquín Gavilá, Thibault de La Motte Rouge, Aleix Prat (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473800.txt.
Description
A peer-reviewed research article from Europe PMC (2026). Background:Despite advances in endocrine therapy, patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (eBC) remain at risk of recurrence (ROR). Chemotherapy is often used in high-risk cases, but not all patients benefit.Objectives:To evaluate whether chemotherapy can be safely omitted in patients with stage II, grade 2/3 HR+/HER2− eBC who convert to low genomic risk (ROR-low) following neoadjuvant ribociclib plus letrozole.Methods:RIBOLARIS (NCT05296746) is an open-label, multicenter phase II trial in patients with stage II, grade 2 or
Catalog record
| CREATOR | Paul Cottu, Tomas Pascual, Jerôme Lemonnier, Huilin Hu, Estelle Roux, Roisin M Connolly, Cynthia X Ma, Antonio C Wolff, Thayane Crestani, Pablo Tolosa, Juan M Ferrero-Cafiero, Antonio Mulero-Sánchez, Fernando Salvador, Guillermo Villacampa, Joaquín Gavilá, Thibault de La Motte Rouge, Aleix Prat |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |